-
|
Reuters –
7:39 AM ET 04/20/2021
BLUEBIRD BIO INC (BLUE): * BLUEBIRD BIO INC (BLUE) - PLANS TO REDUCE AND RESHAPE ITS WORKFORCE, PRIMARILY IN EUROPE. * BLUEBIRD BIO INC (BLUE) - CONTINUES TO WORK WITH REGULATORS TO RESUME ITS CLINICAL STUDIES IN SICKLE CELL DISEASE Source text for Eikon: Further company coverage:
|
-
|
Business Wire –
7:30 AM ET 04/20/2021
bluebird bio, Inc. announced today business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previously reported case of myelodysplastic syndrome in its Phase 1/2 study of LentiGlobin for sickle cell disease, the company’s decision to withdraw ZYNTEGLO™ for transfusion-dependent β-thalassemia from the German market and a targeted reshapi...
|
-
|
Business Wire –
7:00 AM ET 04/14/2021
OXFORD, England & CAMBRIDGE, Mass.
|
-
|
Reuters –
9:53 AM ET 03/29/2021
Bluebird bio Inc (BLUE) said on Monday it has set at $419,500 the wholesale list price of its newly approved multiple myeloma therapy developed with Bristol-Myers Squibb Co. The U.S. FDA on Friday approved the treatment, Abecma, for adult patients with multiple myeloma after four or more prior lines of therapy.
|
-
|
Reuters –
12:47 AM ET 03/27/2021
The U.S. Food and Drug Administration has approved Bristol-Myers Squibb Co (BMY) and bluebird bio Inc's multiple myeloma therapy, ide-cel, acquired as part of its $74 billion buyout of Celgene, the drugmakers said in a joint statement late on Friday.
|
-
|
Reuters –
12:17 AM ET 03/27/2021
* U.S. FOOD AND DRUG ADMINISTRATION APPROVES BRISTOL MYERS SQUIBB'S AND BLUEBIRD BIO'S ABECMA, THE FIRST ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA Source text for Eikon: Further company coverage:
|
-
|
Business Wire –
10:59 PM ET 03/26/2021
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma1 In the pivotal KarMMa trial, the majority of patients achieved rapid, deep and durable responses1 Safety profile of Abecma is well-established and predictable including cytokine release syndrome and neurologic toxicities that are mo...
|
-
|
Business Wire –
5:30 AM ET 03/15/2021
90% of evaluable patients alive and free of major functional disabilities at two years follow-up in Phase 2/3 Starbeam study Patients in long-term follow-up study continue to remain alive and MFD-free through up to nearly seven years of follow-up, suggesting eli-cel stabilizes the progression of disease No reports of graft failure, graft rejection, graft-versus-host disease, replication compet...
|
-
|
Business Wire –
7:00 AM ET 03/10/2021
Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD. bluebird bio has initiated process with regulators to resume clinical studies. Company to hold conference call and webcast today, March 10, 2021, 8:00 AM EST. CAMBRIDGE, Mass.
|
-
|
Business Wire –
8:00 AM ET 02/26/2021
bluebird bio, Inc. today announced that members of the management team will participate in the Cowen 41st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m. ET.
|
-
|
Business Wire –
5:30 PM ET 02/24/2021
First pivotal study of BCMA-directed CAR T cell therapy in triple-class exposed relapsed and refractory multiple myeloma Biologics License Application for ide-cel was accepted by FDA for Priority Review, with a target action date of March 27, 2021 CAMBRIDGE, Mass. The KarMMa study met its primary endpoint of overall response rate and key secondary endpoint of complete response rate.
|
-
|
Reuters –
5:06 PM ET 02/23/2021
bluebird bio Inc: * BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS. * Q4 REVENUE $10.7 MILLION VERSUS $10 MILLION. * Q4 REVENUE ESTIMATE $15.9 MILLION -- REFINITIV IBES DATA. * QTRLY LOSS PER SHARE $3.01. * Q4 EARNINGS PER SHARE VIEW $-2.92 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:
|
-
|
Business Wire –
4:05 PM ET 02/23/2021
bluebird bio, Inc. today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress.
|
-
|
Business Wire –
4:05 PM ET 02/22/2021
bluebird bio, Inc. today announced that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference, Thursday, February 25, at 12:00 p.m. ET.
|
-
|
PR Newswire –
9:00 AM ET 02/19/2021
NEW YORK, Feb. 19, 2021 Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against bluebird bio, Inc. and certain of its officers, on behalf of shareholders who purchased or otherwise acquired bluebird securities between May 11, 2020 and No...
|
-
|
PR Newswire –
8:00 AM ET 02/19/2021
PHILADELPHIA, Feb. 19, 2021 Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. on behalf of investors who purchased bluebird securities between May 11, 2020 and November 4, 2020.
|
-
|
Reuters –
7:09 AM ET 02/16/2021
bluebird bio Inc: * BLUEBIRD BIO ANNOUNCES TEMPORARY SUSPENSION ON PHASE 1/2 AND PHASE 3 STUDIES OF LENTIGLOBIN GENE THERAPY FOR SICKLE CELL DISEASE Source text for Eikon: Further company coverage:
|
-
|
Business Wire –
7:00 AM ET 02/16/2021
bluebird bio, Inc. announced today that the company has placed its Phase 1/2 and Phase 3 studies of LentiGlobin gene therapy for sickle cell disease on a temporary suspension due to a reported Suspected Unexpected Serious Adverse Reaction of acute myeloid leukemia.
|
-
|
GlobeNewswire –
4:05 PM ET 02/15/2021
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against bluebird bio, Inc. in the United States District Court for the Eastern District of New York on behalf of those who purchased or acquired the securities of bluebird between May 11, 2020 and November 4, 2020, inclusive.
|
-
|
PR Newswire –
5:53 PM ET 02/12/2021
NEW YORK, Feb. 12, 2021 Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. and certain of its officers. If you are a shareholder who purchased bluebird securities during the Class Period, you have until April 13, 2021 to ask the Court to appoint you as Lead Plaintiff for the class.
|
Page:
|
Today's and Upcoming Events
-
BLUE to announce Q1 earnings (Unconfirmed)
Past Events (last 90 days)
-
BLUE announced Q4 earnings.
Data provided by Thomson Reuters © 2021
|